JAK1 and cancer: Collectively, our data suggest that TYK2, JAK1 and JAK2 are novel targets that may prove useful to circumvent drug resistance mediated by FGF-2, a growth factor often secreted by cancer cells, or their supporting tissues, and elevated in cancer patients.